Plain-English translation of NCT06796998 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 trial testing a new medication called for people who have been newly diagnosed with marginal zone lymphoma (MZL), a type of blood cancer affecting immune cells. Researchers want to see if this treatment can help control the disease and improve outcomes for patients who haven't received systemic therapy before. You would receive the medication in cycles over several months.
Marginal zone lymphoma is a slow-growing blood cancer, but patients often need effective treatment options. This trial exists to see whether this new medication could become a useful option for people newly diagnosed with this condition.
You likely qualify if…
You likely don't qualify if…
You would receive the study medication () in up to 12 treatment cycles, with each cycle lasting 28 days. Your participation would last up to 3 years total, during which you would have regular clinic visits for infusions, blood tests, imaging scans, and check-ups to monitor how you're responding to the treatment and any side effects.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Izidore Lossos, MD
Collaborators
Genmab, AbbVie
Enrollment target
~25 participants
Started
October 2025
Primary completion
October 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Izidore Lossos, MD
University of Miami
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.